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A B S T R A C T
Background
Naloxone, a speciﬁc opioid antagonist, is available for the treatment of newborn infants with cardiorespiratory or neurological depression
that may be due to intrauterine exposure to opioid. It is unclear whether newborn infants may beneﬁt from this therapy and whether
naloxone has any harmful effects.
Objectives
To determine the effect of naloxone on the need for and duration of neonatal unit stay in infants of mothers who received opioid
analgesia prior to delivery or of mothers who have used a prescribed or non-prescribed opioid during pregnancy.
Search methods
We searched the following databases in February 2018: the Cochrane Central Register of Controlled Trials (the Cochrane Library
2018, Issue 1), MEDLINE (OvidSP), MEDLINE In process &Other Non-Indexed Citations (OvidSP), Embase (OvidSP), CINAHL
(EBSCO),Maternity and Infant Care (OvidSP), and PubMed.We searched for ongoing and completed trials in theWHO International
Clinical Trials Registry Platform and the EUClinical Trials Register. We checked the reference lists of relevant articles to identify further
potentially relevant studies.
Selection criteria
Randomised controlled trials comparing the administration of naloxone versus placebo, or no drug, or another dose of naloxone to
newborn infants with suspected or conﬁrmed in utero exposure to opioid.
Data collection and analysis
We extracted data using the standard methods of Cochrane Neonatal with separate evaluation of trial quality and data extraction by
two review authors and synthesis of data using risk ratio, risk difference, and mean difference.
Main results
We included nine trials, with 316 participants in total, that compared the effects of naloxone versus placebo or no drug in newborn
infants exposed to maternal opioid analgesia prior to delivery. None of the included trials investigated infants born to mothers who had
used a prescribed or non-prescribed opioid during pregnancy. None of these trials speciﬁcally recruited infants with cardiorespiratory
or neurological depression. The main outcomes reported were measures of respiratory function in the ﬁrst six hours after birth. There
is some evidence that naloxone increases alveolar ventilation. The trials did not assess the effect on the primary outcomes of this review
(admission to a neonatal unit and failure to establish breastfeeding).
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Authors’ conclusions
The existing evidence from randomised controlled trials is insufﬁcient to determine whether naloxone confers any important beneﬁts to
newborn infants with cardiorespiratory or neurological depression that may be due to intrauterine exposure to opioid. Given concerns
about the safety of naloxone in this context, it may be appropriate to limit its use to randomised controlled trials that aim to resolve
these uncertainties.
P L A I N L A N G U A G E S U M M A R Y
Naloxone for opioid-exposed newborn infants
Review question
Does naloxone (a drug that counters the negative effects of opioids on breathing) help newborn babies whose mothers have received
opioid pain relief during birth?
Background
When a woman receives opioid medicines for pain relief during labour (for example, pethidine, morphine, and similar drugs), the
opioid can cross over to the baby inside the womb and then reduce the newborn baby’s breathing rate. Naloxone, a drug that counters
the effects of opioids, can be given to the newborn baby to try to prevent or treat problems with breathing. This may reduce the
chance of the baby needing to go to a neonatal unit for help with breathing, and reduce the need for separating mother and baby (and
so help with establishing breastfeeding). Concern exists, however, that naloxone may cause side effects, including possible long-term
developmental problems.
Study characteristics
We found nine completed trials that compared giving to newborn babies, whose mothers had received opioids during labour, either
naloxone or a placebo (’dummy drug’). These trials were conducted more than 30 years ago and they were generally very small including
only about 300 infants in total. Most of the trials did not use reliable methods consistently. Evidence is up-to-date as of February 2018.
Key results
The trials reported the effects of naloxone on the baby’s breathing but did not assess the effect on the need for babies to be cared for
in a neonatal unit (separated from their mother), whether they needed help with breathing, or on breastfeeding success. None of the
trials assessed long-term development. We did not ﬁnd any trials including babies born to mothers who had used opioids (whether
prescribed or non-prescribed) during pregnancy.
Quality of evidence
The available evidence was not sufﬁcient to determine whether giving naloxone to babies whose mothers received opioids during birth
was helpful or harmful.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Naloxone compared to placebo or no drug for opioid-exposed newborn infants
Patient or population: opioid-exposed newborn infants
Setting:
Intervention: naloxone
Comparison: placebo or no drug
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo or no
drug
Risk with Naloxone
Admission to neona-
tal intensive or special
care unit - not reported
- - - - - Primary outcome, not
measured in the in-
cluded trials
Durat ion of neonatal in-
tensive or special care
unit stay - not reported
- - - - - Primary outcome, not
measured in the in-
cluded trials
Failure to establish
breastfeeding prior to
hospital discharge - not
reported
- - - - - Primary outcome, not
measured in the in-
cluded trials
Neurode-
velopmental outcomes
beyond infancy - not re-
ported
- - - - - Primary outcome, not
measured in the in-
cluded trials
Receipt of endotracheal
intubat ion - not re-
ported
- - - - - Secondary outcome, not
measured in the in-
cluded trials
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Receipt of assisted ven-
t ilat ion - not reported
- - - - - Secondary outcome, not
measured in the in-
cluded trials
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval
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B A C K G R O U N D
Description of the condition
Opioid analgesics are available, recommended, and commonly
used for relief ofmaternal pain during labour inmost birth settings
in middle- and high-income countries (Jones 2012; NICE 2017).
Estimates suggest that about one-third to one-half of women re-
ceive opioid analgesia in labour. The extent of use in lower-middle
and low-income settings is less certain (Redshaw 2007; Ullman
2010), though likely to be less than in high-income countries
(James 2012; Ogboli-Nwasor 2014).
The commonly used opioids (pethidine, diamorphine, morphine,
fentanyl) are highly lipid soluble and transplacental transfer to
the fetus occurs rapidly. Intrauterine exposure to maternal opioids
within about four hours of birth may be associated with neurolog-
ical and cardiorespiratory depression and feeding-behaviour prob-
lems in newborn infants (Kumar 2003; Mercer 2007; Reynolds
2010) Concern exists that these adverse effects may delay neona-
tal physiological transition and postnatal adaptation and result in
neonatal unit admission and potentially separation of the infant
and mother. Delay in establishment of effective breastfeeding is an
important possible consequence of this maternal-infant separation
(Burchell 2016; Nissen 1995; Ransjo-Arvidson 2001). Observa-
tional data from surveillance studies have suggested that infants
who experience an acute life-threatening event in the early neona-
tal period or a sudden unexpected early neonatal death are more
likely to have been exposed to maternal opiates during birth, but
a causal link has not been established (Lutz 2016).
Description of the intervention
Naloxone, a speciﬁc “opioid antagonist” that blocks the actions of
opiates on cells, is available for the treatment of neurological and
cardiorespiratory depression in opioid-exposed newborn infants.
The International Liaison Committee on Resuscitation (ILCOR)
has provided guidance on the use of naloxone for newborn infants
(Niermeyer 2001). The advice follows the long-standing recom-
mendation of the American Academy of Pediatrics (AAP) Com-
mittee on Drugs that naloxone should not be used routinely in
opioid-exposed newborn infants but should be “reserved for ad-
junctive therapy in selected infants who have not initiated or es-
tablished independent respiration following ventilation, are signif-
icantly depressed, and have a high probability of being narcotized”
(AAP 1980). These recommendations refer to infants of moth-
ers who have received opioid for analgesia up to four hours prior
to delivery. The dose of naloxone recommended in 1980, 0.01
mg/kg, was later revised to 0.1 mg/kg (AAP 1990). In 2010, an
ILCOR Consensus on Science and Treatment Recommendations
statement updated this advice and suggested that naloxone should
only be given to infants with severe respiratory depression after
positive-pressure ventilation has restored a normal heart rate and
colour (Kattwinkel 2010; Perlman 2010). Despite these guide-
lines, surveys of policy and practice indicate that clinicians con-
tinue to administer naloxone to opioid-exposed newborn infants
in the ﬁrst fewminutes after birth even in the absence of neurolog-
ical or cardiorespiratory depression or before effective supported
ventilation is established (Herschel 2000; Gill 2007).
Opioid-dependent mothers
The AAP Committee on Drugs has advised that naloxone should
not be administered to infants of opioid-dependent mothers as
naloxone may precipitate acute withdrawal and seizures in opioid-
habituated infants (Gibbs 1989; AAP 1998). There are few data
on signiﬁcant adverse events due to naloxone in infants of opioid-
dependent mothers and some authors have recommended a small
dose of naloxone (0.01 mg/kg) as a part of the resuscitation of
such infants (Maas 1990).
Why it is important to do this review
Naloxone should not be regarded as harmless. Concern exists that
naloxone may interfere with the role of the infant’s own natu-
ral opioids in programming metabolic, homonal, and physiolog-
ical processes (Smotherman 1992; De Castro 1993; Szeto 1995).
Given these questions of appropriateness of use and potential long-
term effects, it is important to evaluate the available data on the
use of naloxone in opioid-exposed newborn infants.
O B J E C T I V E S
To determine the effect of naloxone on the need for and duration
of neonatal unit stay in infants of mothers who received opioid
analgesia prior to delivery or ofmotherswhohave used a prescribed
or non-prescribed opioid during pregnancy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Controlled trials using either random or quasi-random patient
allocation.
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Types of participants
Newborn infants of any gestation with suspected or conﬁrmed
exposure to opioids, either:
1. as maternal pain relief prior to delivery;
2. as a result of use during pregnancy.
Types of interventions
Trials comparing naloxone with placebo or no drug, or comparing
more than one dose of naloxone, as part of the management of
newborn infants.
Types of outcome measures
Primary outcomes
Mother-infant separation, effect on breastfeeding, and
neurodevelopment
1. Admission to neonatal intensive or special care unit;
2. Duration of neonatal intensive or special care unit stay;
3. Failure to establish breastfeeding by hospital discharge;
4. Neurodevelopmental outcomes beyond infancy assessed
using validated assessment tools.
Secondary outcomes
Cardio-respiratory function, need for support, and
neurobehavioural outcomes
1. Measures of respiratory function, such as Apgar score, or
arterial blood pH, or arterial or alveolar carbon dioxide tension
measured within the ﬁrst six hours after birth;
2. Receipt of assisted ventilation (any form of mechanical
ventilation including continuous positive airway pressure) in the
neonatal period;
3. Receipt of endotracheal intubation for respiratory support;
4. Duration of assisted ventilation (days);
5. Duration of endotracheal intubation (days);
6. Days from birth to establish full oral feeds independently of
parenteral ﬂuids or nutrition or of enteral tube feeding;
7. Features of opioid withdrawal, using validated behavioural
assessment measures in the neonatal period;
8. Seizures in the neonatal period.
Search methods for identification of studies
We used the standard search strategy of Cochrane Neonatal.
Electronic searches
We updated the searches in February 2018 to identify reports of
trials available since the searches in June 2012. The original search
strategy from June 2012 was checked and updated (Appendix 1).
We searched the following databases on 20 February 2018: the
Cochrane Central Register of Controlled Trials (the Cochrane Li-
brary 2018, Issue 1),MEDLINE (OvidSP),MEDLINE In process
& Other Non-Indexed Citations (OvidSP), Embase (OvidSP),
CINAHL (EBSCO), Maternity and Infant Care (OvidSP), and
PubMed. We imported the search results into reference manage-
ment software and de-duplicated the results against the previous
search results from June 2012. We did not apply any language
restrictions. A search ﬁlter was applied inMEDLINE and Embase
to limit retrieval to randomised controlled trials (Lefebvre 2008;
Lefebvre 2011).
We searched clinical trials registries for ongoing or recently com-
pleted trials (clinicaltrials.gov; the World Health Organization’s
International Trials Registry and Platform www.whoint/ictrp/
search/en/, the ISRCTN Registry, and the EU Clinical Trials
Register https://www.clinicaltrialsregister.eu/). We were unable to
search the metaRegister of Controlled Trials for this update as it
is no longer available.
Searching other resources
We examined the references in studies identiﬁed as potentially rel-
evant for other eligible studies. We also searched the abstracts from
the annual meetings of the Pediatric Academic Societies (1993
to 2018), the European Society for Pediatric Research (1995 to
2017), the UK Royal College of Paediatrics and Child Health
(2000 to 2018) and the Perinatal Society of Australia and New
Zealand (2000 to 2017). We considered trials reported only as
abstracts to be eligible if sufﬁcient information was available from
the report, or from contact with the authors, to fulﬁl the inclusion
criteria.
Data collection and analysis
We used the standard methods of Cochrane Neonatal.
Selection of studies
Two review authors independently screened the title and abstract
of all studies identiﬁed by the above search strategy. We assessed
the full text of any potentially eligible reports and excluded those
studies that did not meet all of the inclusion criteria. We discussed
any disagreements until consensus was achieved.
Data extraction and management
We used a data collection form to extract relevant information
from each included study. Two review authors extracted the data
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separately. We discussed any disagreements with the third review
author until we reached consensus.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias (low,
high, or unclear) of all included trials using the Cochrane ‘Risk
of bias’ tool (Higgins 2017). Any disagreements were resolved by
discussion or by a third assessor. See Appendix 2 for a description
of risk of bias for each domain assessed.
Measures of treatment effect
We calculated risk ratio (RR) and risk difference (RD) for dichoto-
mous data and mean difference (MD) for continuous data, with
respective 95%conﬁdence intervals (CI) usingRevMan 2014 soft-
ware. When it was deemed appropriate to combine two or more
study arms, we obtained the treatment effects from the combined
data using the methods described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
Unit of analysis issues
The unit of analysis was the participating infant in individually
randomised trials and the neonatal unit (or subunit) for cluster-
randomised RCTs. For cluster-randomised RCTs, we planned to
undertake analyses at the level of the individual while accounting
for the clustering in the data using the methods recommended
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Dealing with missing data
We requested outcome data from the trial investigators when these
were unavailable in the report.
Assessment of heterogeneity
Two authors assessed clinical heterogeneity, with a meta-analysis
conducted only when both authors agreed that study participants,
interventions, and outcomes were sufﬁciently similar.
We examined the treatment effects of individual trials and hetero-
geneity between trial results by inspecting the forest plots. We cal-
culated the I² statistic for each analysis to quantify inconsistency
across studies and described the percentage of variability in effect
estimates that may be due to heterogeneity rather than to sampling
error. If we detected moderate or high heterogeneity (I² > 50%),
we would explore the possible causes (for example, differences in
study design, participants, interventions, or completeness of out-
come assessments).
Assessment of reporting biases
We intended to conduct a funnel-plot analysis if there were data
from more than 10 trials included in a meta-analysis.
Data synthesis
We used ﬁxed-effect models for meta-analysis (as per Cochrane
Neonatal recommendations). Where moderate or high hetero-
geneity existed, we planned to examine the potential causes in
subgroup and sensitivity analyses.
Quality of evidence
We used the Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) approach to assess the qual-
ity of evidence for the primary outcomes and key secondary
outcomes we considered most relevant to parents and caregivers
(Schünemann 2013; Appendix 3):
1. Admission to neonatal intensive or special care unit;
2. Duration of neonatal intensive or special care unit stay;
3. Failure to establish breastfeeding by hospital discharge;
4. Neurodevelopmental outcomes beyond infancy;
5. Receipt of assisted ventilation;
6. Receipt of endotracheal intubation.
Two authors independently assessed the quality of the evidence for
each of these outcomes. We considered evidence from randomised
controlled trials initially as high-quality but downgraded this evi-
dence one level for serious (or two levels for very serious) limita-
tions based upon the following: design (risk of bias), consistency
across studies, directness of the evidence, precision of estimates,
and presence of publication bias. We used the GRADEpro GDT
Guideline Development Tool to create a ‘Summary of ﬁndings’
table to report the quality of the evidence.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses:
1. dose of naloxone < 0.1 mg/kg body weight;
2. dose of naloxone ≥ 0.1 mg/kg body weight.
Sensitivity analysis
We planned sensitivity analyses to determine if the ﬁndings were
affected by including only studies of adequate methodology (low
risk of bias), deﬁned as adequate randomisation and allocation
concealment, blinding of intervention and measurement, and <
10% loss to follow-up.
R E S U L T S
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Description of studies
Results of the search
The update search returned 588 records. After de-duplication, 120
titles and abstracts were screened. The records that did not meet
the inclusion criteria were excluded at title and abstract screening,
and no studies were ordered for full-text screening. The study
selection process is illustrated in Figure 1. We did not identify any
planned or ongoing studies.
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Figure 1. Study flow diagram: review update
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Included studies
We included nine trials and these are described in the table
’Characteristics of included studies’. Two of these were reported
in the same article (Dick 1978a; Dick 1978b).
A total of 316 infants participated in the included trials. All
were undertaken in the 1970s or early 1980s. The participants
were term newborn infants whose mothers had received pethidine
(meperidine) for pain relief up to six hours prior to delivery. None
of the trials speciﬁcally restricted participation to infants with car-
diorespiratory or neurological depression following opioid expo-
sure. In most trials, the intervention appears to have been given in
the ﬁrst ﬁve minutes after birth. In two trials, naloxone was given
later; at 30 minutes (Gerhardt 1977) or at one hour (Welles 1984)
after birth.Naloxonewas administered via the intramuscular route
in four trials, and in the other ﬁve via the umbilical venous route.
The dose of naloxone used ranged from 0.01 to 0.07 mg/kg with
the exception of one study in which a total dose of 0.2 mg was
given (Wiener 1977b). The outcomes most commonly assessed
were measures of respiratory effort such as Apgar scores, blood
gases values, or other measures of alveolar ventilation.
None of the trials examined the effects of naloxone in infants of
mothers who had used a prescribed or non-prescribed narcotic
during pregnancy.
Excluded studies
We excluded two studies (Martin 1972; Brice 1979b; see
Characteristics of excluded studies).
Risk of bias in included studies
All of the trials were small and none presented a sample size calcu-
lation. The ’Risk of bias’ assessment was hampered by incomplete
reporting of trial methods (most likely due to the studies pre-dat-
ing current reporting guidelines). Across included studies, several
’Risk of bias’ domains had to be assessed as ’unclear’ as details were
not reported in the publications.
Allocation
Three studies reported adequate measures of allocation conceal-
ment and random sequence generation, reducing the risk of selec-
tion bias in these trials. The remaining six reports did not provide
sufﬁcient details of measures to ensure allocation concealment or
random sequence generation.
Blinding
Caregivers or assessorswere likely to have beenblinded inﬁve of the
trials. Three trials reported that outcome assessors were unblinded
and in one trial it was unclear whether outcome assessors were
blinded.
Incomplete outcome data
All of the trials appear to have achieved complete or near-complete
follow-up of infants recruited although none of the trials under-
took follow-up beyond the ﬁrst three days after birth.
Selective reporting
The risk of reporting bias was unclear across the included studies
as trial protocols were not available (most likely due to the age of
the studies), However, for eight of the nine included trials, there
was no reason to suspect selective reporting.
One trial was considered to be at high risk of selective reporting as
the paper stated that certain outcomes (including one primary and
one secondary outcome) would not be reported in the publication
but would be available from the corresponding author. Due to
the age of the study, we were unable to make contact with any of
the authors and were, hence, unable to access these data despite
knowing that they were collected during the trial.
Other potential sources of bias
In seven out of nine included studies, no other potential sources
of bias were identiﬁed and the risk of other bias was, consequently,
judged to be low. One study was stopped early because the ran-
domisation code was broken. However, further details pertaining
to the causes of this breach of protocol or its consequences were
not discussed in the paper. One other study was reported to have
been funded by the pharmaceutical company that manufactured
the intervention. Both these trials were judged to have an unclear
risk of other biases.
Effects of interventions
See: Summary of ﬁndings for the main comparison Naloxone
compared to placebo or no drug for opiate-exposed newborn
infants
Primary outcomes
Admission to neonatal intensive or special care unit:
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Not reported.
Duration of neonatal intensive or special care unit stay:
Not reported.
Failure to establish breastfeeding by hospital discharge:
Not reported.
Neurodevelopmental outcomes beyond infancy assessed
using validated assessment:
Not reported.
Secondary outcomes
Measures of respiratory function:
Eight of the trials presented data on measures of respiratory func-
tion measured within the ﬁrst six hours after birth. There were
no statistically signiﬁcant differences in the Apgar score (Bonta
1979), respiratory rate (Evans 1976), time to sustained respiration
(Brice 1979a), minute ventilation (Gerhardt 1977), or blood gas
parameters (Bonta 1979; Dick 1978a; Dick 1978b).
Four trials assessed measures of alveolar ventilation (Brice 1979a;
Evans 1976; Wiener 1977a; Wiener 1977b). At 30 minutes and
four hours post intervention, the expired carbon dioxide output
and alveolar ventilation rate were statistically signiﬁcantly higher,
and the alveolar carbon dioxide tension lower, in the naloxone
group (Analysis 1.1; Analysis 1.2; Analysis 1.3; Figure 2; Figure
3; Figure 4). We detected statistical heterogeneity in analysis 1.2
(alveolar carbon dioxide tension) and analysis 1.3 (alveolar ven-
tilation). In each analysis (alveolar carbon dioxide tension at 30
minutes (1.2.2) and at four hours (1.2.4) and alveolar ventilation
at 30 minutes (1.3.3) and at four hours (1.3.5)), the heterogene-
ity arose from the same study (Wiener 1977b). This study used a
larger dose of naloxone, and naloxone was given intramuscularly
compared with intravenously in the other studies. In the analyses
of alveolar carbon dioxide tension at 30 minutes and four hours
(1.2.2 and 1.2.4), Wiener 1977b showed a greater effect size in
favour of naloxone compared to the other studies included in these
analyses. The same was true for analyses of alveolar ventilation at
30 minutes and four hours.
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Figure 2. Forest plot of comparison: 1 Naloxone versus placebo or no drug, outcome: 1.1 Expired carbon
dioxide output (mL/kg/min).
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Figure 3. Forest plot of comparison: 1 Naloxone versus placebo or no drug, outcome: 1.2 Alveolar carbon
dioxide tension (kPa).
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Figure 4. Forest plot of comparison: 1 Naloxone versus placebo or no drug, outcome: 1.3 Alveolar
ventilation (mL/kg/minute).
Receipt of assisted ventilation in the neonatal period:
Not reported.
Receipt of endotracheal intubation for respiratory support:
Not reported.
Duration of assisted ventilation:
Not reported.
Duration of endotracheal intubation: not reported.
Days from birth to establish full oral feeds independently of
parenteral ﬂuids or nutrition or of enteral tube feeding:
Not reported.
Features of opioid withdrawal:
The studies that reported the Scanlon Behavioural Score (Bonta
1979; Brice 1979a) and the Brazelton Neonatal Behavioural As-
sessment Score (Brice 1979a; Welles 1984) did not ﬁnd any sta-
tistically signiﬁcant differences. One trial reported the Broussard
Neonatal Perception Inventory at 72 hours and found statisti-
cally signiﬁcantly “less optimal behaviour” in the naloxone group
(Welles 1984). Standard deviations were not reported in any of
these studies. Wiener 1977b found that the time taken to habitu-
14Naloxone for opioid-exposed newborn infants (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ate to a sound-speciﬁc stimulus within the ﬁrst 48 hours was sta-
tistically signiﬁcantly lower in infants who received intramuscular
naloxone versus placebo. Wiener 1977a stated that there were no
“important differences” in habituation to auditory stimulus be-
tween infants who received intravenous naloxone versus placebo.
Seizures in the neonatal period:
Not reported.
Subgroup analyses
Dose of naloxone < 0.1 mg/kg body weight:
All of the included trials used this dose.
Dose of naloxone ≥ 0.1 mg/kg body weight:
None of the included trials used this dose.
Sensitivity analyses
Only one trial report was assessed as having an overall ’low risk of
bias’ deﬁned as adequate randomisation and allocation conceal-
ment, blinding of intervention and measurement, and < 10% loss
to follow-up (Bonta 1979). Data from this trial were not included
in any of the meta-analyses.
D I S C U S S I O N
Summary of main results
We identiﬁed nine small trials that compared naloxone versus
placebo or no drug for treating newborn infants who had been
exposed to maternal opioid analgesia prior to delivery. Our up-
date search in 2018 identiﬁed no trials investigating naloxone in
this context. The trials evaluated the effect of naloxone on infants
exposed to opioid analgesia in labour. None examined the use of
naloxone in infants who had been exposed to opioid in utero dur-
ing pregnancy, for example, due to maternal opioid-dependence.
None of the included trials provided any data on any of the pri-
mary outcomes of this review, that is, maternal separation (need for
neonatal unit admission), effect on breastfeeding, and neurodevel-
opment beyond infancy. With regard to secondary outcome mea-
sures, most trials only reported measures of respiratory function
and neurological behaviour in the ﬁrst 48 hours after birth. The
analyses ofmeasures of alveolar carbondioxide tension and alveolar
ventilation were affected by statistical heterogeneity caused by one
study showing greater effect sizes in favour of naloxone (Wiener
1977b). This could be attributed to the greater dose of naloxone
used in this study and possibly also to the fact that naloxone was
given via the intramuscular route in this study (compared to in-
travenous delivery in all other studies). When given intravenously,
naloxone is absorbed more effectively but has a shorter half-life
compared with intramuscular administration (Perlman 2010).
Overall completeness and applicability of
evidence
The trials provided some evidence that infants who received nalox-
one had higher indices of alveolar ventilation, higher expired car-
bon dioxide levels, and lower alveolar carbon dioxide tensions than
control infants. The clinical signiﬁcance of these ﬁndings is un-
clear since the infants recruited to the trials did not appear to have
been selected because of cardiorespiratory depression. Infants with
low Apgar scores for up to ﬁve minutes were not eligible for in-
clusion in two trials (Bonta 1979; Welles 1984). There were no
trial data that assessed whether treatment with naloxone affected
the need for, or the duration of, mechanical respiratory support
including positive-pressure ventilation. All of the included trials
were conducted over 30 years ago. The evidence is likely to be of
limited relevance in the clinical context for which naloxone is rec-
ommended by the ILCOR, that is, for opioid-exposed newborn
infants with respiratory depression despite appropriate ventilation
(Kattwinkel 2010; Niermeyer 2001; Perlman 2010). The ILCOR
Consensus on Science rates neurodevelopmental measures as a
critical outcome, reﬂecting the high importance clinicians, policy
makers, and parents place on this outcome. None of the trials in-
cluded in this review reported any neurodevelopmental measures
beyond infancy.
Quality of the evidence
All of the trials were small and had various methodological weak-
nesses including uncertain allocation concealment that may have
biased their ﬁndings and the ﬁndings of this review (Figure 5). As-
certainment or surveillance biases may also be present since care-
givers and clinicians in some of the trials were aware of the allo-
cated intervention. Although follow-up assessment was complete
in the trials, none assessed outcomes beyond the ﬁrst few days after
birth.
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Figure 5. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Potential biases in the review process
Following standard Cochrane methods, we tried to minimise the
risk of biases introduced during the review process. The literature
search was conducted by an information specialist with the aim to
identify and retrieve all relevant evidence published since the last
update of this review in 2012. We searched conference abstracts
and reference lists of potentially eligible publications. There re-
mains a risk that studies could have been missed due to index-
ing errors in the databases. Throughout the review process, we
followed methods to minimise the risk of reviewer error and bias
(study selection carried out independently and in duplicate).
Agreements and disagreements with other
studies or reviews
The 2010 ILCOR Consensus on Science (Kattwinkel 2010;
Perlman 2010) does not recommend naloxone as part of the initial
resuscitation of newborn infants. This recommendation is based
largely on the same body of evidence as this review. The current
ILCOR Consensus on Science published in 2015 (Perlman 2015)
does not mention naloxone at all, reﬂecting the lack of new evi-
dence in this area.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available trial data do not provide any evidence that admin-
istration of naloxone to infants exposed in utero to opioid during
delivery affects any important outcomes. The efﬁcacy and safety
of naloxone for infants chronically exposed in utero to opioids in
opioid-dependent women has not been assessed.
Implications for research
Clinicians and service-users may consider it appropriate to under-
take a randomised controlled trial to determine if naloxone confers
any important beneﬁts to newborn infants with cardiorespiratory
or neurological depression that may be due to intrauterine expo-
sure to opioids. This trial should assess outcomes that are relevant
to the infant, family, and caregivers, such as the need for admis-
sion to a neonatal unit for ongoing respiratory support. In view of
the concerns that naloxone may interfere with the role of endoge-
nous opioids in neuroendocrine programming and on behaviour
(De Castro 1993; Smotherman 1992; Szeto 1995), follow-up as-
sessment beyond infancy should determine neurodevelopmental
outcomes which have been judged to be of critical importance by
ILCOR (Perlman 2015).
There are no trials concerning the use of naloxone for the treatment
of infants that were chronically exposed to opioids in utero, most
likely due to concerns that administration of naloxonemight cause
seizures in these infants (AAP 1998; Gibbs 1989).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bonta 1979
Methods Randomised controlled trial
Participants 43 term newborn infants whose mothers had received routine narcotic analgesia within
6 hours of delivery. Infants delivered in breech presentation or by Caesarean section, and
infants with Apgar score less than 6 at 1 minute, were excluded
Interventions 1. Intramuscular naloxone (0.02 mg/kg body weight): n = 22
2. Placebo (normal saline): n = 21
Outcomes Apgar score at 5 minutes, capillary blood gas values at 1, 2 and 4 hours of life, neurobe-
havioural assessment at 1, 4, and 24 hours
Notes NICU, North America, late 1970s
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generated in pharmacy to produce se-
quentially numbered ampoules containing either nalox-
one or placebo
Allocation concealment (selection bias) Low risk Sequentially numbered ampoules (unable to predict
whether naloxone or placebo)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled study using sequentially numbered
ampoules - personnel unlikely to have been aware of in-
fants’ group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The testers were not aware of which infants received
naloxone or placebo”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete ascertainment of outcomes
Selective reporting (reporting bias) Unclear risk No protocol (though no reason to suspect selective re-
porting)
Other bias Low risk No reason to suspect any other bias
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Brice 1979a
Methods Randomised controlled trial
Participants 50 term newborn infants whose mothers had received intramuscular pethidine within 4
hours of delivery
Interventions 1. Naloxone administered via the umbilical vein (0.01 or 0.02 mg/kg body weight): n =
26
2. No drug: n = 24
Outcomes Time to sustained respiration, expired carbon dioxide output, and alveolar ventilation
up to 24 hours of life, Brazelton Neonatal Behavioral Assessment Score and Scanlon
Behavioral Score within the ﬁrst 24 hours of life
Notes NICU, United Kingdom, late 1970s
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Divided at random”, no further details reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessors blinded for Scanlon developmental assessment
(but results not reported for this outcome), no further
details reported on blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up
Selective reporting (reporting bias) High risk “The results for the serial blood-gas analyses, the Brazel-
ton and Scanlon scores ... are not presented in full. These
may be obtained from [the corresponding author] on re-
quest.”
Other bias Unclear risk Study was supported by a grant from Winthrop Labora-
tories (pharmaceutical company that manufactured the
intervention)
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Dick 1978a
Methods Randomised controlled trial
Participants 40 newborn infants, of unspeciﬁed gestation, whose mothers had been given intravenous
pethidine in labour
Interventions 1. Naloxone, via the umbilical vein immediately after birth (0.02 mg/kg): n = 10
2. Naloxone (0.03 mg/kg): n = 10
3. Naloxone (0.04 mg/kg): n = 10
4. No drug: n = 10
Outcomes Capillary blood gas pH and partial pressure of carbon dioxide and of oxygen at 1, 5, 10,
30, 60 and 120 minutes of life
Notes NICU, Germany, late 1970s
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “randomly distributed”, no further details
reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up
Selective reporting (reporting bias) Unclear risk No protocol (though no reason to suspect selective re-
porting)
Other bias Low risk No reason to suspect any other bias
Dick 1978b
Methods Randomised controlled trial
Participants 30 newborn infants, of unspeciﬁed gestation, whose mothers had been given intravenous
pethidine in labour
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Dick 1978b (Continued)
Interventions 1. Naloxone, via the umbilical vein immediately after birth (either 0.04 mg/kg or 0.04
mg total): n = 20
2. Placebo: n = 10
Outcomes Capillary blood gas pH, partial pressure of carbon dioxide and of oxygen, and calculated
base excess at 1, 5, 10, 30, 60 and 120 minutes of life
Notes NICU, Germany, late 1970s
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “randomly distributed”, no further details
reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Placebo and the varying amounts of Naloxone were dis-
tributed in equal amounts and thus indistinguishable”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Examiner and follow-up examiner were not informed
about the agent or the dose”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up
Selective reporting (reporting bias) Unclear risk No protocol (though no reason to suspect selective re-
porting)
Other bias Low risk No reason to suspect any other bias
Evans 1976
Methods Randomised controlled trial
Participants 44 newborn infants, of gestation 38 to 42 weeks, delivered spontaneously or by forceps,
whose mothers had been given pethidine in labour
Interventions 1. Naloxone administered via the umbilical vein at 1 minute of age (0.04 mg total): n =
20
2. No drug: n = 24
Outcomes Time to ﬁrst breath, time to onset of sustained respiration, Apgar score at 5 minutes,
alveolar carbon dioxide tension, alveolar ventilation, and ventilation rate at 10 minutes
and 30 minutes of life
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Evans 1976 (Continued)
Notes NICU, Wales, mid 1970s
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “randomly allocated”, no further details re-
ported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up
Selective reporting (reporting bias) Unclear risk No protocol (though no reason to suspect selective re-
porting)
Other bias Low risk No reason to suspect any other bias
Gerhardt 1977
Methods Randomised controlled trial
Participants 20 term newborn infants, born vaginally, whose mothers had received intravenous pethi-
dine within 3 hours of delivery
Interventions 1. Intramuscular naloxone at 30 minutes of life (0.01 mg/kg): n = 14
2. Placebo: n = 10
Outcomes Respiratory rate, tidal volume, minute ventilation, end-tidal carbon dioxide tension, and
the ventilatory response to inhalation of 4% carbon dioxide
Notes NICU, North America, mid 1970s
Risk of bias
Bias Authors’ judgement Support for judgement
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Gerhardt 1977 (Continued)
Random sequence generation (selection
bias)
Unclear risk “By random number ... infants were selected”, no further
details reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo-controlled study but unclear if personnel were
aware of infants’ allocation to groups
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Near-complete follow-up but 2 infants in each group
were excluded post-randomisation because “lung com-
pliance values changed more than 25% between the two
determinations”
Selective reporting (reporting bias) Unclear risk No protocol (though no reason to suspect selective re-
porting)
Other bias Low risk No reason to suspect any other bias
Welles 1984
Methods Randomised controlled trial
Participants 27 newborn infants, of gestation 38 to 42 weeks, whose mothers had received pethidine
during labour. Infants with Apgar scores less than 8 at 1 minute, or less than 9 at 5
minutes were not eligible for inclusion
Interventions 1. Naloxone at about 1 hour of age (0.1 mg total, presumed intramuscularly, but this
was not stated explicitly): n = 14
2. Placebo (normal saline): n = 13
Outcomes BrazeltonNeonatal Behavioral Assessment Score at 12-24 hours of life and after a further
48 hours, and the Broussard Neonatal Perception Inventory after the second Brazelton
assessment
Notes NICU, Sweden, early 1980s
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
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Welles 1984 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up
Selective reporting (reporting bias) Unclear risk No protocol (though no reason to suspect selective re-
porting)
Other bias Low risk No reason to suspect any other bias
Wiener 1977a
Methods Randomised controlled trial
Participants 28 newborn infants, of gestation 38 to 42weeks, whosemothers had been given pethidine
in labour
Interventions 1. Naloxone administered via the umbilical vein at 1 minute of age (0.04 mg total): n =
10
2. Normal saline placebo: n = 18
Outcomes Alveolar carbon dioxide tension, carbon dioxide excretion, alveolar ventilation, feeding
behaviour, and habituation to a sound-speciﬁc stimulus up to 48 hours of life
Notes NICU, Wales, mid 1970s
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random allocation in pharmacy
Allocation concealment (selection bias) Low risk Coded ampoules
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Naloxone or normal salinewere “chosenblind at random”
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Wiener 1977a (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Likely to have beenblindedbut not stated explicitly either
way in the paper
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up
Selective reporting (reporting bias) Unclear risk No protocol (though no reason to suspect selective re-
porting)
Other bias Unclear risk The study was stopped early because the randomisation
code was broken after 28 infants had been enrolled
Wiener 1977b
Methods Randomised controlled trial
Participants 30 newborn infants, of gestation 38 to 42weeks, whosemothers had been given pethidine
in labour
Interventions 1. Intramuscular naloxone at 1 minute of age (0.2 mg total): n = 15
2. Intramuscular normal saline placebo: n = 15
Outcomes Alveolar carbon dioxide tension, carbon dioxide excretion, alveolar ventilation, feeding
behaviour (mean sucking frequencies and pressures, and mean milk consumption), and
habituation to a sound-speciﬁc stimulus up to 48 hours of life
Notes NICU, Wales, mid 1970s
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random allocation in pharmacy
Allocation concealment (selection bias) Low risk Coded ampoules
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Naloxone or normal salinewere “chosenblind at random”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Likely to have beenblindedbut not stated explicitly either
way in the paper
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete follow-up
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Wiener 1977b (Continued)
Selective reporting (reporting bias) Unclear risk No protocol (though no reason to suspect selective re-
porting)
Other bias Low risk No reason to suspect other bias
NICU :Neonatalintensivecareunit
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Brice 1979b This report of pharmacokinetic data in infants who received either intravenous or intramuscular naloxone was unlikely
to be a randomised comparison
Martin 1972 This report was unlikely to be a randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Naloxone versus placebo or no drug
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Expired carbon dioxide output
(mL/kg/min)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 At 15 minutes 1 50 Mean Difference (IV, Fixed, 95% CI) 1.30 [0.15, 2.45]
1.2 At 30 minutes 3 108 Mean Difference (IV, Fixed, 95% CI) 0.90 [0.39, 1.40]
1.3 At 90 minutes 1 50 Mean Difference (IV, Fixed, 95% CI) 0.50 [-0.17, 1.17]
1.4 At 4 hours 2 58 Mean Difference (IV, Fixed, 95% CI) 0.86 [0.12, 1.59]
2 Alveolar carbon dioxide tension
(kPa)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 At 10 minutes 1 44 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.01, -0.19]
2.2 At 30 minutes 3 102 Mean Difference (IV, Fixed, 95% CI) -0.87 [-1.16, -0.59]
2.3 At about 35 minutes 1 20 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.90, 0.70]
2.4 At 4 hours 2 58 Mean Difference (IV, Fixed, 95% CI) -0.87 [-1.25, -0.50]
3 Alveolar ventilation
(mL/kg/minute)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 At 10 minutes 1 44 Mean Difference (IV, Fixed, 95% CI) 13.0 [-16.88, 42.88]
3.2 At 15 minutes 1 50 Mean Difference (IV, Fixed, 95% CI) 16.0 [-8.53, 40.53]
3.3 At 30 minutes 4 152 Mean Difference (IV, Fixed, 95% CI) 36.03 [21.92, 50.14]
3.4 At 90 minutes 1 50 Mean Difference (IV, Fixed, 95% CI) 14.0 [-6.30, 34.30]
3.5 At 4 hours 2 58 Mean Difference (IV, Fixed, 95% CI) 55.30 [33.92, 76.69]
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Analysis 1.1. Comparison 1 Naloxone versus placebo or no drug, Outcome 1 Expired carbon dioxide output
(mL/kg/min).
Review: Naloxone for opioid-exposed newborn infants
Comparison: 1 Naloxone versus placebo or no drug
Outcome: 1 Expired carbon dioxide output (mL/kg/min)
Study or subgroup Naloxone Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 15 minutes
Brice 1979a 26 11.6 (1.8) 24 10.3 (2.3) 100.0 % 1.30 [ 0.15, 2.45 ]
Subtotal (95% CI) 26 24 100.0 % 1.30 [ 0.15, 2.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
2 At 30 minutes
Brice 1979a 26 9.9 (1.3) 24 9.1 (1.8) 33.1 % 0.80 [ -0.08, 1.68 ]
Wiener 1977a 10 7.6 (1.3) 18 7.1 (1) 29.5 % 0.50 [ -0.43, 1.43 ]
Wiener 1977b 15 8.4 (1.2) 15 7.1 (1.1) 37.5 % 1.30 [ 0.48, 2.12 ]
Subtotal (95% CI) 51 57 100.0 % 0.90 [ 0.39, 1.40 ]
Heterogeneity: Chi2 = 1.67, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.49 (P = 0.00048)
3 At 90 minutes
Brice 1979a 26 8.3 (1.1) 24 7.8 (1.3) 100.0 % 0.50 [ -0.17, 1.17 ]
Subtotal (95% CI) 26 24 100.0 % 0.50 [ -0.17, 1.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
4 At 4 hours
Wiener 1977a 10 5.9 (2.8) 18 5.8 (1.4) 15.7 % 0.10 [ -1.75, 1.95 ]
Wiener 1977b 15 6.8 (0.9) 15 5.8 (1.3) 84.3 % 1.00 [ 0.20, 1.80 ]
Subtotal (95% CI) 25 33 100.0 % 0.86 [ 0.12, 1.59 ]
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Chi2 = 1.65, df = 3 (P = 0.65), I2 =0.0%
-2 -1 0 1 2
Favours control Favours naloxone
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Analysis 1.2. Comparison 1 Naloxone versus placebo or no drug, Outcome 2 Alveolar carbon dioxide
tension (kPa).
Review: Naloxone for opioid-exposed newborn infants
Comparison: 1 Naloxone versus placebo or no drug
Outcome: 2 Alveolar carbon dioxide tension (kPa)
Study or subgroup Naloxone Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 10 minutes
Evans 1976 20 5.3 (0.6) 24 5.9 (0.8) 100.0 % -0.60 [ -1.01, -0.19 ]
Subtotal (95% CI) 20 24 100.0 % -0.60 [ -1.01, -0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.84 (P = 0.0045)
2 At 30 minutes
Evans 1976 20 5 (0.6) 24 5.5 (0.8) 48.4 % -0.50 [ -0.91, -0.09 ]
Wiener 1977a 10 4.7 (0.6) 18 5.6 (1) 23.6 % -0.90 [ -1.49, -0.31 ]
Wiener 1977b 15 4.3 (0.4) 15 5.8 (1) 28.0 % -1.50 [ -2.05, -0.95 ]
Subtotal (95% CI) 45 57 100.0 % -0.87 [ -1.16, -0.59 ]
Heterogeneity: Chi2 = 8.21, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 5.94 (P < 0.00001)
3 At about 35 minutes
Gerhardt 1977 12 5.4 (0.74) 8 5.5 (0.98) 100.0 % -0.10 [ -0.90, 0.70 ]
Subtotal (95% CI) 12 8 100.0 % -0.10 [ -0.90, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
4 At 4 hours
Wiener 1977a 10 5.4 (0.7) 18 5.6 (0.9) 39.0 % -0.20 [ -0.80, 0.40 ]
Wiener 1977b 15 4.5 (0.3) 15 5.8 (0.9) 61.0 % -1.30 [ -1.78, -0.82 ]
Subtotal (95% CI) 25 33 100.0 % -0.87 [ -1.25, -0.50 ]
Heterogeneity: Chi2 = 7.86, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 4.55 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.14, df = 3 (P = 0.25), I2 =28%
-2 -1 0 1 2
Favours naloxone Favours control
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Analysis 1.3. Comparison 1 Naloxone versus placebo or no drug, Outcome 3 Alveolar ventilation
(mL/kg/minute).
Review: Naloxone for opioid-exposed newborn infants
Comparison: 1 Naloxone versus placebo or no drug
Outcome: 3 Alveolar ventilation (mL/kg/minute)
Study or subgroup Naloxone Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 10 minutes
Evans 1976 20 169 (57) 24 156 (41) 100.0 % 13.00 [ -16.88, 42.88 ]
Subtotal (95% CI) 20 24 100.0 % 13.00 [ -16.88, 42.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
2 At 15 minutes
Brice 1979a 26 179 (41) 24 163 (47) 100.0 % 16.00 [ -8.53, 40.53 ]
Subtotal (95% CI) 26 24 100.0 % 16.00 [ -8.53, 40.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
3 At 30 minutes
Brice 1979a 26 176 (39) 24 165 (50) 31.9 % 11.00 [ -14.00, 36.00 ]
Evans 1976 20 166 (61) 24 143 (39) 20.8 % 23.00 [ -7.95, 53.95 ]
Wiener 1977a 10 185 (38) 18 150 (38) 23.1 % 35.00 [ 5.63, 64.37 ]
Wiener 1977b 15 228 (39) 15 147 (41) 24.3 % 81.00 [ 52.36, 109.64 ]
Subtotal (95% CI) 71 81 100.0 % 36.03 [ 21.92, 50.14 ]
Heterogeneity: Chi2 = 14.01, df = 3 (P = 0.003); I2 =79%
Test for overall effect: Z = 5.00 (P < 0.00001)
4 At 90 minutes
Brice 1979a 26 156 (35) 24 142 (38) 100.0 % 14.00 [ -6.30, 34.30 ]
Subtotal (95% CI) 26 24 100.0 % 14.00 [ -6.30, 34.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
5 At 4 hours
Wiener 1977a 10 136 (104) 18 122 (39) 10.2 % 14.00 [ -52.93, 80.93 ]
Wiener 1977b 15 176 (30) 15 116 (33) 89.8 % 60.00 [ 37.43, 82.57 ]
Subtotal (95% CI) 25 33 100.0 % 55.30 [ 33.92, 76.69 ]
Heterogeneity: Chi2 = 1.63, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 5.07 (P < 0.00001)
Test for subgroup differences: Chi2 = 10.95, df = 4 (P = 0.03), I2 =63%
-100 -50 0 50 100
Favours control Favours naloxone
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A P P E N D I C E S
Appendix 1. Electronic search strategy
Search strategies
Cochrane Central Register of Controlled Trials (CENTRAL)
Wiley http://onlinelibrary.wiley.com/
Issue 1 of 12, January 2018
Searched on: 20th February 2018
Records retrieved: 14
#1 MeSH descriptor: [Infant, Newborn] explode all trees 15665
#2 MeSH descriptor: [Premature Birth] this term only 597
#3 (neonat* or neo next nat*):ti,ab 14017
#4 (newborn* or new next born* or newly next born*):ti,ab 6237
#5 (preterm or preterms or pre next term or pre next terms):ti,ab 9039
#6 (preemie* or premie or premies):ti,ab 21
#7 (prematur* near/3 (birth* or born or deliver*)):ti,ab 1118
#8 (low near/3 (birthweight* or birth next weight*)):ti,ab 3505
#9 (lbw or vlbw or elbw):ti,ab 1221
#10 infan*:ti,ab 27709
#11 (baby or babies):ti,ab 4644
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 44720
#13 MeSH descriptor: [Naloxone] explode all trees 1833
#14 naloxone:ti,ab 1826
#15 narcan:ti,ab 5
#16 MeSH descriptor: [Narcotic Antagonists] this term only 1129
#17 ((narcotic or opiate or opioid) near/3 antagonist*):ti,ab 1031
#18 #13 or #14 or #15 or #16 or #17 3280
#19 #12 and #18 76
#20 #12 and #18 in Trials 68
#21 #12 and #18 Publication Year from 2007 to 2018 14
Line #20 shows the number of hits in CENTRAL only.
Key
MeSH descriptor = indexing term (MeSH heading)
* = truncation
:ti,ab = terms in either title or abstract ﬁelds
NEAR/3 = terms within three words of each other (any order)
NEXT = terms are next to each other
CINAHL
via EBSCO http://www.ebsco.com/
Inception to 19th February 2018
Searched on: 20th February 2018
Records retrieved: 83
S1 MH “Infant, Newborn+” 107,105
S2 MH “Infant, Low Birth Weight+” 10,646
S3 MH “Infant, Premature” 17,476
S4 (MH “Childbirth, Premature”) 7,235
S5 TI ( neonat* or neo-nat* ) OR AB ( neonat* or neo-nat* ) 45,560
S6 TI ( newborn* or new-born* or newly N1 born* ) OR AB ( newborn* or new-born* or newly N1 born* ) 21,724
S7 TI ( preterm or preterms or pre-term or pre-terms ) OR AB ( preterm or preterms or pre-term or pre-terms) 22,267
S8 TI ( preemie* or premie or premies ) OR AB ( preemie* or premie or premies ) 239
S9 TI ( prematur* N3 (birth* or born or deliver*) ) OR AB ( prematur* N3 (birth* or born or deliver*) ) 3,179
S10 TI ( low N3 (birthweight* or birth-weight*) ) OR AB ( low N3 (birthweight* or birth-weight*) ) 8,753
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S11 TI ( lbw or vlbw or elbw ) OR AB ( lbw or vlbw or elbw ) 2,359
S12 TI infan* OR AB infan* 79,927
S13 TI ( baby or babies ) OR AB ( baby or babies ) 23,527
S14 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 190,257
S15 (MH “Naloxone+”) 3,344
S16 TI naloxone OR AB naloxone 1,874
S17 TI narcan OR AB narcan 38
S18 (MH “Narcotic Antagonists”) 1,598
S19 TI ( ((narcotic or opiate or opioid) N3 antagonist*) ) OR AB ( ((narcotic or opiate or opioid) N3 antagonist*) ) 796
S20 S15 OR S16 OR S17 OR S18 OR S19 4,922
S21 S14 AND S20 140
S22 S14 AND S20 Limiters - Publication Year: 2007-2018 83
Key
MH = indexing term (CINAHL heading)
+ = exploded CINAHL heading
* = truncation
TI = words in the title
AB = words in the abstract
N3 = terms within three words of each other (any order)
Embase
OvidSP http://ovidsp.ovid.com/
1974 to 2018 February 18
Searched on: 19th February 2018
Records retrieved: 50
A search strategy developed by Lefebvre et. al. to identify randomised trials in Embase was used to limit retrieval to clinical trials (lines
23-37) (Lefebvre 2008).
1 exp infant/ (983099)
2 newborn/ (535610)
3 prematurity/ (91829)
4 premature labor/ (40137)
5 exp low birth weight/ (53021)
6 (neonat$ or neo nat$).ti,ab. (302625)
7 (newborn$ or new born$ or newly born$).ti,ab. (184612)
8 (preterm or preterms or pre term or pre terms).ti,ab. (86396)
9 (preemie$ or premie or premies).ti,ab. (214)
10 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (18958)
11 (low adj3 (birthweight$ or birth weight$)).ti,ab. (38393)
12 (lbw or vlbw or elbw).ti,ab. (9710)
13 infan$.ti,ab. (460096)
14 (baby or babies).ti,ab. (85499)
15 or/1-14 (1360576)
16 naloxone/ (39568)
17 naltrexone/ (13293)
18 naloxone.ti,ab. (25894)
19 narcan.ti,ab. (120)
20 narcotic antagonist/ (2171)
21 ((narcotic or opiate or opioid) adj3 antagonist$).ti,ab. (13795)
22 16 or 17 or 18 or 19 or 20 or 21 (58022)
23 random$.ti,ab. (1269278)
24 factorial$.ti,ab. (32048)
25 crossover$.ti,ab. (64838)
26 cross-over$.ti,ab. (28769)
27 placebo$.ti,ab. (268419)
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28 (doubl$ adj blind$).ti,ab. (186242)
29 (singl$ adj blind$).ti,ab. (20605)
30 assign$.ti,ab. (330112)
31 allocat$.ti,ab. (123986)
32 volunteer$.ti,ab. (228781)
33 Crossover Procedure/ (54337)
34 double blind procedure/ (146460)
35 Randomized Controlled Trial/ (487494)
36 single blind procedure/ (30408)
37 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 (1963083)
38 15 and 22 and 37 (141)
39 animal/ (1835634)
40 exp animal experiment/ (2167842)
41 nonhuman/ (5322101)
42 (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or cats or bovine or sheep).ti,ab,sh.
(5689708)
43 39 or 40 or 41 or 42 (8403753)
44 exp human/ (19255041)
45 human experiment/ (396693)
46 44 or 45 (19256570)
47 43 not (43 and 46) (6322301)
48 38 not 47 (119)
49 limit 48 to yr=“2007 -Current” (50)
Key:
/ = indexing term (EMTREE heading)
exp = exploded EMTREE heading
$ = truncation
.ti,ab. = terms in either title or abstract ﬁelds
adj3 = terms within three words of each other (any order)
.sh. = terms in the EMTREE heading ﬁeld
Maternity and Infant Care
OvidSP http://ovidsp.ovid.com/
1971 to December 2017
Searched on: 20th February 2018
Records retrieved: 65
1 (neonat$ or neo nat$).mp. (42157)
2 (newborn$ or new born$ or newly born$).mp. (38013)
3 (preterm or preterms or pre term or pre terms).mp. (23364)
4 (preemie$ or premie or premies).mp. (50)
5 (prematur$ adj3 (birth$ or born or deliver$)).mp. (6532)
6 (low adj3 (birthweight$ or birth weight$)).mp. (10998)
7 (lbw or vlbw or elbw).mp. (2765)
8 infan$.mp. (82242)
9 (baby or babies).mp. (27270)
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 (117850)
11 naloxone.mp. (74)
12 Naltrexone.mp. (10)
13 narcan.mp. (1)
14 ((narcotic or opiate or opioid) adj3 antagonist$).mp. (20)
15 11 or 12 or 13 or 14 (91)
16 10 and 15 (65)
Key
$ = truncation
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.mp. = multi-purpose ﬁeld search - includes terms in either title, abstract, keyword heading, name of substance, original title or subject
heading ﬁelds
adj3 = terms within three words of each other (any order)
MEDLINE
OvidSP http://ovidsp.ovid.com/
1946 to February Week 2 2018
Searched on: 19th February 2018
Records retrieved: 89
The Cochrane highly sensitive search strategy for identifying randomized trials in MEDLINE (sensitivity-maximizing version) was
used to limit retrieval to clinical trials (lines 19-29) (Lefebvre 2011).
1 exp Infant, Newborn/ (560906)
2 Premature Birth/ (10524)
3 (neonat$ or neo nat$).ti,ab. (214766)
4 (newborn$ or new born$ or newly born$).ti,ab. (140975)
5 (preterm or preterms or pre term or pre terms).ti,ab. (55474)
6 (preemie$ or premie or premies).ti,ab. (137)
7 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (12830)
8 (low adj3 (birthweight$ or birth weight$)).ti,ab. (28169)
9 (lbw or vlbw or elbw).ti,ab. (6466)
10 infan$.ti,ab. (360691)
11 (baby or babies).ti,ab. (56440)
12 or/1-11 (903657)
13 exp Naloxone/ (23951)
14 naloxone.ti,ab,rn. (24723)
15 narcan.ti,ab,rn. (57)
16 Narcotic Antagonists/ (12351)
17 ((narcotic or opiate or opioid) adj3 antagonist$).ti,ab. (11217)
18 or/13-17 (35523)
19 randomized controlled trial.pt. (453101)
20 controlled clinical trial.pt. (92131)
21 randomized.ab. (352150)
22 placebo.ab. (170252)
23 drug therapy.fs. (1991268)
24 randomly.ab. (244938)
25 trial.ab. (364753)
26 groups.ab. (1531866)
27 or/19-26 (3828607)
28 exp animals/ not humans/ (4424434)
29 27 not 28 (3265481)
30 12 and 18 and 29 (233)
31 limit 30 to yr=“2007 -Current” (89)
Key
/ = indexing term (MeSH heading)
exp = exploded MeSH heading
$ = truncation
.ti,ab. = terms in either title or abstract ﬁelds
adj3 = terms within three words of each other (any order)
.pt.= terms in the publication type ﬁeld
.fs.= ﬂoating subheading
MEDLINE (Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily)
OvidSP http://ovidsp.ovid.com/
16th February 2018
Searched on: 19th February 2018
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Records retrieved: 27
1 exp Infant, Newborn/ (436)
2 Premature Birth/ (16)
3 (neonat$ or neo nat$).ti,ab. (19923)
4 (newborn$ or new born$ or newly born$).ti,ab. (10342)
5 (preterm or preterms or pre term or pre terms).ti,ab. (7080)
6 (preemie$ or premie or premies).ti,ab. (8)
7 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (1180)
8 (low adj3 (birthweight$ or birth weight$)).ti,ab. (2673)
9 (lbw or vlbw or elbw).ti,ab. (727)
10 infan$.ti,ab. (31472)
11 (baby or babies).ti,ab. (6278)
12 or/1-11 (56812)
13 exp Naloxone/ (13)
14 naloxone.ti,ab,rn. (993)
15 narcan.ti,ab,rn. (6)
16 Narcotic Antagonists/ (13)
17 ((narcotic or opiate or opioid) adj3 antagonist$).ti,ab. (526)
18 or/13-17 (1307)
19 12 and 18 (27)
PubMed
http://www.ncbi.nlm.nih.gov/pubmed/
Searched on: 20th February 2018
Records retrieved: 246
The Cochrane highly sensitive search strategy for identifying randomized trials in PubMed (sensitivity-maximizing version) was used
to limit retrieval to clinical trials (Lefebvre 2011).
Search (((((((((((((((((((“Infant, Newborn”[Mesh])) OR (“Premature Birth”[Mesh])) OR (((neonat*[Title/Abstract]) ORneo nat*[Title/
Abstract]) OR neo-nat*[Title/Abstract])) OR (((((newborn*[Title/Abstract]) OR new born*[Title/Abstract]) OR new-born*[Title/
Abstract]) OR newly born*[Title/Abstract]) OR newly-born*[Title/Abstract])) OR ((((((preterm[Title/Abstract]) OR preterms[Title/
Abstract]) OR pre term[Title/Abstract]) OR pre-term[Title/Abstract]) OR pre terms[Title/Abstract]) OR pre-terms[Title/Ab-
stract])) OR (((preemie*[Title/Abstract]) OR premie[Title/Abstract]) OR premies[Title/Abstract])) OR ((prematur*[Title/Abstract])
AND birth*[Title/Abstract])) OR ((prematur*[Title/Abstract]) AND born[Title/Abstract])) OR ((prematur*[Title/Abstract]) AND
deliver*[Title/Abstract])) OR ((low[Title/Abstract]) AND birthweight*[Title/Abstract])) OR ((low[Title/Abstract]) AND birth
weight*[Title/Abstract])) OR ((low[Title/Abstract]) AND birth-weight*[Title/Abstract])) OR (((lbw[Title/Abstract]) OR vlbw[Title/
Abstract]) OR elbw[Title/Abstract])) OR (infan*[Title/Abstract])) OR ((baby[Title/Abstract]) OR babies[Title/Abstract]))) AND
((((((((“Naloxone”[Mesh])) OR (naloxone)) OR (narcan)) OR ((narcotic[Title/Abstract]) AND antagonist*[Title/Abstract])) OR
((opiate[Title/Abstract]) AND antagonist*[Title/Abstract])) OR (“Narcotic Antagonists”[Mesh:noexp])) OR ((opioid[Title/Ab-
stract]) AND antagonist*[Title/Abstract])))) AND (((((((((((randomized controlled trial[Publication Type])) OR (controlled clinical
trial[Publication Type])) OR (randomized[Title/Abstract])) OR (placebo[Title/Abstract])) OR (drug therapy[MeSH Subheading]))
OR (randomly[Title/Abstract])) OR (trial[Title/Abstract])) OR (groups[Title/Abstract]))) NOT (animals[mh] NOT humans[mh]))
Key
[Mesh] = exploded indexing term (MeSH heading)
[mh] = exploded indexing term (MeSH heading)
[Mesh:NoExp] = indexing term (MeSH heading) not exploded
* = truncation
[Title/Abstract]) = terms in either title or abstract ﬁelds
[Publication Type] = terms in the publication type ﬁeld
[MeSH Subheading] = MeSH subheading
Trial registers
ClinicalTrials.gov
http://www.clinicaltrials.gov/
Searched on: 20th February 2018
Records retrieved: 5
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1. Naloxone AND (infant OR infants OR newborn OR newborns OR premature OR prematurity OR neonate OR neonates OR
neonatal OR pretermOR pretermsOR preemie OR preemies OR premie OR premies OR birthweight OR baby OR babies) - 3 studies
2. Narcan AND (infant OR infants OR newborn OR newborns ORpremature ORprematurity ORneonate OR neonates OR neonatal
OR preterm OR preterms OR preemie OR preemies OR premie OR premies OR birthweight OR baby OR babies) - 2 studies
WHO International Clinical Trials Registry Platform
http://apps.who.int/trialsearch/AdvSearch.aspx
Searched on: 20th February 2018
Records retrieved: 9
1. Naloxone in title, clinical trials in children - 5 results
2. Naloxone in intervention ﬁeld, clinical trials in children - 4 results
3. Narcan in title, clinical trials in children - 0
4. Narcan in intervention ﬁeld, clinical trials in children - 0 results
EU Clinical Trials Register
https://www.clinicaltrialsregister.eu/ctr-search/search
Searched on: 20th February 2018
Records retrieved: 0
1. naloxone textword search, limited to newborn or preterm new born infants age ﬁlter - 0 results
2. narcan textword search, limited to newborn or preterm new born infants age ﬁlter - 0 results
Appendix 2. Risk of bias tool
1. Sequence generation (checking for possible selection bias). Was the allocation sequence adequately generated?
For each included study, we categorised the method used to generate the allocation sequence as:
• low risk (any truly random process e.g. random number table; computer random number generator);
• high risk (any non-random process e.g. odd or even date of birth; hospital or clinic record number); or
• unclear risk.
2. Allocation concealment (checking for possible selection bias). Was allocation adequately concealed?
For each included study, we categorised the method used to conceal the allocation sequence as:
• low risk (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
• high risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth); or
• unclear risk
3. Blinding of participants and personnel (checking for possible performance bias). Was knowledge of the allocated intervention
adequately prevented during the study?
For each included study, we categorised the methods used to blind study participants and personnel from knowledge of which
intervention a participant received. Blinding was assessed separately for different outcomes or class of outcomes. We categorised the
methods as:
• low risk, high risk or unclear risk for participants; and
• low risk, high risk or unclear risk for personnel.
4. Blinding of outcome assessment (checking for possible detection bias). Was knowledge of the allocated intervention adequately
prevented at the time of outcome assessment?
For each included study, we categorised the methods used to blind outcome assessment. Blinding was assessed separately for different
outcomes or class of outcomes. We categorised the methods as:
• low risk for outcome assessors;
• high risk for outcome assessors; or
• unclear risk for outcome assessors.
5. Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). Were
incomplete outcome data adequately addressed?
For each included study and for each outcome, we described the completeness of data including attrition and exclusions from the
analysis. We noted whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with
the total randomised participants), reasons for attrition or exclusion, where reported, and whether missing data were balanced across
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groups or were related to outcomes. Where sufﬁcient information was reported or supplied by the trial authors, we re-included missing
data in the analyses. We categorised the methods as:
• low risk (< 20% missing data);
• high risk (≥ 20% missing data); or
• unclear risk.
6. Selective reporting bias. Are reports of the study free of suggestion of selective outcome reporting?
For each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. For
studies in which study protocols were published in advance, we compared prespeciﬁed outcomes versus outcomes eventually reported
in the published results. If the study protocol was not published in advance, we contacted study authors to gain access to the study
protocol. We assessed the methods as:
• low risk (where it was clear that all of the study’s prespeciﬁed outcomes and all expected outcomes of interest to the review had
been reported);
• high risk (where not all the study’s prespeciﬁed outcomes had been reported; one or more reported primary outcomes were not
prespeciﬁed outcomes of interest and were reported incompletely and so could not be used; study failed to include results of a key
outcome that would have been expected to have been reported); or
• unclear risk.
7. Other sources of bias. Was the study apparently free of other problems that could put it at a high risk of bias?
For each included study, we described any important concerns we had about other possible sources of bias (for example, whether there
was a potential source of bias related to the speciﬁc study design or whether the trial was stopped early due to some data-dependent
process). We assessed whether each study was free of other problems that could put it at risk of bias as:
• low risk;
• high risk;
• unclear risk
If needed, we explored the impact of the level of bias through undertaking sensitivity analyses.
Appendix 3. GRADE
GRADE considers that evidence from randomised controlled trials initially is “high” quality but that assessment may be downgraded
based on consideration of any of ﬁve areas:
• design (risk of bias);
• consistency across studies;
• directness of the evidence;
• precision of estimates; and
• presence of publication bias.
This results in an assessment of the quality of a body of evidence in one of four grades:
1. High: We are very conﬁdent that the true effect lies close to that of the estimate of the effect.
2. Moderate: We are moderately conﬁdent in the effect estimate: the true effect is likely to be close to the estimate of the effect, but
there is a possibility that it is substantially different.
3. Low: Our conﬁdence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
4. Very low: We have very little conﬁdence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
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WH A T ’ S N E W
Last assessed as up-to-date: 20 February 2018.
Date Event Description
9 May 2018 New search has been performed This updates the review “Naloxone for opioid-exposed
newborn infants” (Moe-Byrne 2013).
9 May 2018 New citation required but conclusions have not changed Search updated in February 2018.
No new trials added.
Background and discussion updated.
Risk of Bias tables updated.
Summary of ﬁndings table added.
H I S T O R Y
Protocol ﬁrst published: Issue 1, 2002
Review ﬁrst published: Issue 4, 2002
Date Event Description
31 July 2012 New citation required but conclusions have not changed Search updated in June 2012.
No new trials added.
Background and discussion updated.
10 June 2008 Amended Converted to new review format.
14 March 2007 New search has been performed This review updates “Naloxone for narcotic-exposed
newborn infants”, published in the Cochrane Database
of Systematic Reviews, The Cochrane Library, Issue 4,
2002 (McGuire 2002).
Our electronic searchwas updated in February 2007.No
new trials that fulﬁlled eligibility criteria were identiﬁed.
We re-categorised studies that were previously listed as
“studies awaiting assessment”. Four of these were ab-
stracts presenting data that was also presented in in-
cluded substantive publications. These are now listed as
secondary publications. One study was excluded
18 June 2002 New citation required and conclusions have changed Substantive amendment
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C O N T R I B U T I O N S O F A U T H O R S
Thirimon Moe-Byrne and Jennifer Brown searched and screened the studies for inclusion, assessed the methodological quality of the
trials, and extracted and entered the relevant information and data from each included study independently. All authors completed the
ﬁnal review.
D E C L A R A T I O N S O F I N T E R E S T
None.
S O U R C E S O F S U P P O R T
Internal sources
• Centre for Reviews and Dissemination, University of York, UK.
External sources
• National Institute for Health Research (NIHR), UK.
This report is independent research funded by a UK NIHR Cochrane Programme Grant (16/114/03). The views expressed in this
publication are those of the review authors and are not necessarily those of the National Health Service, the NIHR, or the UK
Department of Health.
• Vermont Oxford Network, USA.
Cochrane Neonatal Reviews are produced with support from Vermont Oxford Network, a worldwide collaboration of health
professionals dedicated to providing evidence-based care of the highest quality for newborn infants and their families.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For the 2018 update, we made the following changes:
• Neurodevelopment promoted to primary outcome because ILCOR has ranked this as a “critical” outcome across the board in
the 2015 consensus statement (Perlman 2015).
• We changed the title of the review from “opiate” to “opioid”, as a broader term. The original protocol title was “Naloxone for
narcotic-exposed newborn infants”.
• We added the methodology and plan for ’Summary of ﬁndings’ tables and GRADE recommendations, which were not included
in the original protocol or the previously published review.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
∗Prenatal Exposure Delayed Effects; Naloxone [∗therapeutic use]; Narcotic Antagonists [∗therapeutic use]; Narcotics [∗adverse effects];
Randomized Controlled Trials as Topic; Respiratory Insufﬁciency [chemically induced; ∗drug therapy]
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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